Clinical trial application for DR30206 for injection approved
October 19, 2026
Source: drugdu
38
Huadong Medicine, according to the announcement, the holding subsidiary, Zhejiang Daer Biotechnology Co., Ltd., recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (NMPA). The clinical trial application for DR30206 for injection submitted by Daer Biotechnology has been approved. The indication is: This product is intended as consolidation therapy for patients with locally advanced/unresectable (stage III) non-small cell lung cancer who have not progressed after concurrent/sequential chemoradiotherapy.
Source: https://finance.eastmoney.com/a/202610163898618389.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Telix teams up with Ekalia (IBA-Framatome JV) to scale up astatine-211 production in the U.S., advancing targeted alpha therapy October 19, 2026
- Haihe Biopharma’s oral paclitaxel (Bairuisu) approved for breast cancer, the world’s first oral paclitaxel October 19, 2026
- Beijing Fuyuan Pharmaceuticals aims to become the first generic version of a hypertension drug. October 19, 2026
- The first generic version of Ponatinib from Yuandong Bio has been approved for marketing October 19, 2026
- Warrant Pharmaceuticals’ active pharmaceutical ingredients, terbutaline sulfate and indocyanine green, have been approved for marketing October 19, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
